Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceuticals Policy topic
No spam. Unsubscribe anytime.
Senate passes wide‑ranging pharmacy bill; includes expanded access to naloxone and limits on listing pharmaceutical reps — controversial 'death‑penalty' sales条
Summary
A broad measure on prescription drugs and pharmacy regulation passed the Senate after amendments. The bill includes studies on access to mifepristone, expanded Narcan access rules, a provision to limit public listing of pharmaceutical representatives' personal information and new restrictions aimed at preventing in‑state supply of certain drugs when sold with knowledge they will be used to carry out executions — a provision that prompted significant debate about interstate commerce and was later narrowed in committee votes.
The Senate approved a multipart bill addressing prescription drugs, pharmacy practice and related public‑safety items.
Sponsor Senator Maroney summarized the amendment: sections include a study of access to mifepristone, removal of full addresses for pharmaceutical representatives from the Department of Consumer Protection website (public list reduced to first name and last initial), authority for veterinary technicians to fill prescriptions under veterinarian supervision, attestation requirements for wholesalers that they will not sell drugs used in executions, and fixes to Narcan distribution rules to remove onerous temperature‑control and alarm requirements for secure boxes.
The floor debate turned particularly contentious over the sections (4–12) that would prohibit in‑state manufacturers or wholesalers from knowingly selling drugs or devices if they intended they be used to execute a death sentence in another jurisdiction. Senators raised commerce‑clause concerns, enforcement questions (how to define 'actual knowledge'), and potential unintended consequences (shortages or lawsuits). A proposed strike amendment (Senate Amendment B) that would remove the death‑penalty‑related attestation failed; supporters said the change reflected state moral policy and nonparticipation in executions, while opponents warned of likely legal challenges and practical problems for manufacturers.
Other sections of the bill addressing Narcan access and veterinary prescription practice received bipartisan support. The Senate adopted one or more amendments and passed the bill on a roll call vote.
